Drugs / EGFR Antisense DNA
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00903461 | Apr 2012 → Mar 2015 | head and neck squamous cell carcinoma | University of Pittsburgh | Terminated | No outcome recorded |
| Phase 1 | NCT00009841 | Mar 1999 → Mar 2002 | head and neck cancer | University of Pittsburgh | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01592721 | Apr 2013 → Feb 2022 | head and neck cancer, squamous cell carcinoma | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGFR Antisense DNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01592721 ↗ |
| Action | Inhibit | “inhibits EGFR at the intracellular level” NCT01592721 ↗ |
| Modality | Antisense oligonucleotide | “EGFR antisense DNA” NCT00009841 ↗ |
| Route | Other | “Patients receive EGFR antisense DNA and DC-chol liposomes intratumorally weekly for 4 weeks.” NCT00009841 ↗ |
| Target | EGFR | “an antisense gene targeting the EGFR” NCT01592721 ↗ |